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Ora l  P resentat ions  
how weI1 peripheral counts predicted CD34 recovery during the 
first collection, linear regression was performed using WBC, 
platelet (Ph) count, and PCD34 count as independent variables. 
Data were log transformed. WBC and Plt both were correlated 
with CD34 yield (p of slope = 0.000 and 0.012, respectively). 
However, coefficients of correlation (r^2) were low (0.137 and 
O. 162) rendering these parameters of little value for predicting the 
behavior of the individual patient, in contrast, the correlation of 
CD34 yield and PCD34 count was stri~ng (rA2=0.958). Cross 
tabs analysis of PCD34 performed on the day of leukapheresis 
revealed that a cutoffof 10 PCD34/microliter gave a 92.6% prob- 
ability of collecting in a single leukapheresis, and a 98.8% proba- 
bility after 1 or more leukaphereses. We are using these data to 
construct an algorithm to schedule patients for leukapheresis, with 
particular attention to the difficult o mobilize patient. 
GVH/GVL 
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ANTIGEN PRESENTING CELLS IN THE LIVER RECRUITE ACTIVATED 
ALLOGENEIC CDS+ T CELLS TO ELICIT HEPATIC GRAFT-VERSUS- 
HOST DISEASE 
ZhmTg, I( l; Shlomchik, D~D.:; Joe, G J; LoTtbo,ati11, JJ; Zhu, J. I; Gian- 
nola, D. ~ ; Enzerson, S.G. i 1. ~ledicine, University of PemT.~vlvania School 
of ~lediciJze, Philadelphia, PA; 2. ~}zle University, New Haven, CT. 
Graft-versus-host disease (GVHD) induced by donor T cells rec- 
og~aizing minor histcompatibility antigens (miHAs) primarily target 
specific organs uch as the liver, skin and intestine. YVe have previous- 
ly demonstrated that rapid activation donor T cells by host antigen 
presenting ceils (APCs) is ufficient o both activation and effector 
phases of acute GVHD. However, it is not well understood how 
these organs become the main targets of activated alloreactive T cells. 
In order to measure whether tissue resident APCs might play a criti- 
cal role in initiating the local development of acute GVHD, we selec- 
tively depleted host macrophages and DCs from the livers and 
spleens but not from the skin, peripheral lymph nodes (PLN), or 
mesenteric lymph nodes (MLN) of C57BL/6 (B6) mice by intra- 
venous administration f liposomal-ehlodronate prior to allogeneic 
bone marrow transplantation. Depletion of host hepatic and splenic 
macrophages and DCs significantly inhibited the proliferation of 
donor C3H.SW CDS+ T cells in the spleen but not in the PLN or 
MLN of B6 mice. Such organ-selective depletion of host tissue APCs 
also markedly reduced the trafficking of allogeneic CD8+ T cells into 
the livers and spleens, but not PLN and MLN, of B6 recipients as 
compared to hat of the control mice. Acute hepatic, but not cnta- 
neous, GVHD was inhibited as well, resulting in improved survival of 
liposomal-chlodronate tr ated B6 recipients. YVhen C3H.SW 
CD8+T cells were activated in normal B6 recipients, recovered and 
adoptively transferred into secondary B6 recipients, activated onor 
CD8+ T cells rapidly migrated into the livers and spleens of control 
B6 recipients, but was markedly decreased in B6 mice that were 
depleted of hepatic and splenic macrophages and DCs. Interestingly, 
host APC activation of donor T cells induced the expression of 
CCR5 followed by CCR1 and CCR4. In contrast, CCR7 that is 
expressed on naive T cells was dramatically reduced on these activat- 
ed CD8+ T cells. Thus, tissue resident APCs control the local 
recnlitment of allo-reactive donor T cells and the subsequent devel- 
opment of acute GVHD via the coordinated expression of chemokine 
receptor CCR7, CCR5 and CCR1 on actiwlted onor CD8 T cells. 
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A PHASE I/ll STUDY OF RECOMBINANT HUMAN KERATINOCYTE 
GROWTH FACTOR (KGF) IN PATIENTS WITH HIGH RISK HEMATO- 
LOGIC MALIGNANCIES UNDERGOING MISMATCHED RELATED OR 
UNRELATED DONOR TRANSPLANT 
Reynolds, C.M.; Fe~v:nr< ft.; Raymond, H.; B'~vntn, T.; Ratamnha'natholv, 
U.; Aysh, L.; Levine, ft.; }~anik, G.; Cooke, R~; Silvel; S.; Redo!y, P.; 
Beckel; ?,I.; Ube~Ti, ft. Ulfiversitv of Michiglm, Ann A'rbol, MI. 
In murine BMT systems, the administration of KGF reduces 
small bowel damage and serum systemic inflammatory mediators 
resulting in less clinical GVHD while preserving GVL and 
improving leukemia free survival. We initiated aphase I/II, sched- 
ule escalation trial of KGF plus standard GVHD prophylaxis 
(tacrolimus and methotrexate) in patients with an unrelated or 
tILA mismatched donor who are therefore at high risk for devel- 
oping acute GVHD (AGVHD). All study patients (n=I 1) had high 
risk hematologic malignancies. Patients received a full-intensity 
conditioning regimen of CVB (cyclophosphamide, VP-16, 
BCNU), BAC (busulfan, cytarabine, cyclophosphamide) or 
CyTBI (cyclophosphamide, TBI 1200 cGy). KGF (60 mcg/kg/day 
intravenously) was administered for 3 consecutive days prior to 
the conditioning regimen, and then for 3 consecutive days each 
week starting Day 0, escalating in 2 week blocks. One DLT has 
been observed (CTC grade 3 skin rash on Day +6), One patient 
with progressive NHL prior to transplant received only 3 doses 
and was removed from the study, and a second patient with pri- 
mary refractory NHL died of sepsis within two weeks of trans- 
plant. Nine patients are fidly evaluable for AGVHD (table). All 
four patients receiving 6 doses of KGF developed AGVHD (one 
each with overall grades 1 to 4). Of five patients receiving either 
12 or 18 doses of KGF, one patient had grade 1 and one had grade 
2 AGVHD. Six patients are in remission at last follow-up. These 
preliminary results at the higher KGF doses compare fnvorably to 
historical controls in which the incidence of AGVHD is 50 to 
75% in patients receiving unrelated or HLA-mismatched allo- 
grafts. The study continues to accrue patients and will escalate the 
administration schedule of KGF up to 36 doses based on the inci- 
dence of DLTs. 
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SIROLIMUS (RAPAMYCIN) FOR TREATMENT OF STEROID-REFRACTO- 
RY CHRONIC GRAFT VERSUS HOST DISEASE 
Com'iel, D.R.; Hicks, 1C; Saliba, R.; Cohen, A.; It)politi, C.; Hsu, 1:; 
Donato, ~i.; Gi~vlt, S.; Khom'i, L; Hosing', C.; De LiTna, :~l.ff.; Ander- 
sson, B.; Gajewski, ft.; Ne~mzmm, ft.; CTJampliJl, R. Blood and 3/lmv'ozv 
Transplantation, UT ~ID Anderson Cancer Center, Hozzsron, TX. 
Chronic graft versus host disease (cGVHD) occnrs in approxi- 
mately 50% of patients following hematopoietic stem cell trans- 
plant. VVe conducted a phase II trial in 29 patients with steroid- 
refractory cGVHD (median age 42 years, range 18-69) utilizing 
tacrolimusin combination with sirolimns. At the time of sirolimus 
initiation, 20 patients (69%) had extensive cGVHD, and 9 
patients hinited. Disease sites included: lower GI tract (n=2), liver 
(n=6), skin (n=24), oral/vaginal mucosae (n=5), ocular (n=3), and 
upper GI tract (n=l). Eight patients had s~n involvement (30%) 
with scleroderma. The onset of eGVHD at study enrolhnent 
included 15 relapsing" (52%), 12 progressive (42%), and 2 (7%) de 
novo cases. All patients had failed multiple previous lines of 
immunosuppression (median 4, range 2-14) prior to sirolimus. 
Patients received sirolirnus uspension orally at a loading dose of 6 
rag, followed by a maintenance dose of 2 nag/day to maintain 
trough concentrations of 5-15 mg/dl. Additional monitoring 
inchided weekly lipid panels, }LMG CoA reductase inhibitors and 
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fibric acid derivatives used as needed to control hyperlipidemia. 
The overall response rate was 68% (n=18), with 5 CR and 13 PR. 
Of the remaining patients, 6 failed to respond, 3 had progressive 
disease and 2 patients were not evaluable. Response by disease 
location included skin (n=17), lower GI (n=l), liver (n=l), mucosal 
(n=3), and ocular (n=2). 6/8 (75%) of patients with scleroderma 
responded. Overall, sirolimus was tolerated well, with mostly 
reversible adverse ffects which included: hypertriglyceridemia 
(22, 76%), hypereholesterolemia (8, 28%), hypertension (i6, 
55%), thrombocytopenia (11, 38%), and leukopenia (6, 21%). 
Fourteen (48%) patients remain alive, with 11 deaths occurring 
from progression of cGVHD. Overall smMval since sirolimus ini- 
tiation was 42%, (95% CI 23-61). Combination therapy with 
sirolituus and tacrolimus i  an active regimen for the treatment of 
steroid refractory cGVHD, particularly in patients with steroid- 
refractory scleroderma. Based on these preliminary findings, fur- 
ther investigation of sirolimus in combination with tacrolimus for 
the management of cGVHD is warranted. 
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DONOR PRETREATMENT WITH PROGENIPOIETIN-I PREVENTS 
ACUTE GRAFT-VERSUS-HOST DISEASE IN AN IL-IO DEPENDENT 
FASHION AND AUGMENTS THE GRAFT-VERSUS-LEUKEMIA EFFECT 
3dacDo,ald, K.P/; Rowe, IA~; Filipich, Cd; k~glply, J.K.:; Ferrava, 
ff.L.S; Hill, G.R. s 1. The QaeeJzslmzd hzstitute of Medical Resea~vh, 
Brisba~ze, QLD, AHs't~wlia; 2. Phavmacia, St Lo,is, MO; 3. U, iversity 
of Michigal~, dTz~ d 'bo'~; MI. 
We have studied the ability of stem cell grafts mobilised with the 
chimeric G-CSF and FLT-3 receptor agonist Progenipoietin-1 
(ProGP-1) to separate graft-versus-host disease (GVHD) and graft- 
versus-leukemia (GVL) in the well described B6 ~ B6D2F1 stem 
ceil transplant (SCT) nmdel. ProGP-1, G-CSF or control diluent 
was administered to donor B6 mice. ProGP 1 expanded all cell ine- 
ages in the spleen and blood with dramatic expansion of dendritic 
cells (DC) and granulocyte-nmnocyte lin ages (2-log increase). 
Transplant survival was 0%, 50% and 90% in recipients of control, 
G-CSF and ProGP-I treated allogeneic donor splenocytes respec- 
tively (P<0.0001). Donor pretreatment with ProGP-1 allowed a 2 to 
4-fold escalation in T cell dose over that possible with G-CSF. 
Donor CD4 T cells from allogeneic SCT recipients of ProGP 1 
splenocytes demonstrated ananergic response to host antigen (pro- 
liferation and cytokine) while CD8 T cell cytotoxicity to host anti 
gens remained intact. Neither CD1 lc hi DC nor "plasmacytoid" 
CDllc'I~m/B220 hi DC |roln ProGP-1 treated onor animals con- 
ferred protection from GVIID. Conversely, when equa] numbers of 
purified T cells from contro], G-CSF or ProGP-1 treated allogene- 
ic donors were added to allogeneic T-cell depleted control spleen, 
survival at day 60 was 0%, 15% and 90% respectively (P<0.0001). 
The improved survival in recipients of ProGP-1 T cells was associ- 
ated with reductions in systemic TNF0c generation (Control v 
ProGP-l: 227--82 v 35+14 pg/ml, P<0.01) and GVHD of the GI 
tract (senti-quantitative GVHD score: 19.5+2.1 v 9.5+0.4, P<0.01). 
Splenocytes from ProGP-1, but not control nor G-CSF treated ani- 
mals produced large amounts of IL-I0 to CpG. Furthermore, 
ProGP-1 expanded IL-lff/- splenocytes tailed to prevent GVI-ID 
relative to wild type (survival: 0% v 67%, P<0.001). In GVL experi- 
ments shown below, host type P815 was added to grafts on day 0 
and survival was monitored for 70 days after SCT. Recipients of 
ProGP-1 splenocytes containing either low or high T ceil doses rel 
ative to G-CSF had improved overall survival due to reduced 
GVtlD mortality and leukemia relapse (~P<0.05 v G-CSF). These 
data confirm that donor pretreatment with ProGP-1 prevents 
GVHD in an IL 10 and T cell dependent fashion and is superior to 
G-CSF in separating GVHD and GVL after allogeneic SCT. 
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APPLICATION OF IMMUNE-THERAPEUTIC INTERVENTIONS AFTER 
ALLOGENEIC STEM-CELL TRANSPLANTATION BASED ON MRD 
DETECTION WITH COMBINED MORPHOLOGICAL AND CYTOGENETIC 
ANALYSIS 
S,~imo,i, A. 1; Trakhte~brot, L. 2; Bielo~:ai, B.1; Re#hart, 3/i. 3; Rothmm~, 
R.2; Torel~, d.;; Rechavi, G.2; Nagler, dd 1. Bolle Jllavvow Tva71s'pla~l- 
tatio~z, Cha#n Sheba Medical Ce1~teT, el~Hashomer, Israel; 2. Hema- 
tology a,d Pediat'de Hemato-O,eology, Chah, Sheba 3Iedieal Ce~zteJ, 
Tel-Hashomer; 3. Bio View LtD, Nes-Zio~ea. 
Recurrent disease remains a major obstacle to cure after allo- 
geneic transplantation. Detection of MRD allows timely applica- 
tion of immune-therapeutic interventions such as early withdrawal 
of immunesuppression or DLI to those destined to relapse. We 
used a novel system (Duet-TM, BioView), which provides com- 
bined morphological and cytogenetic analysis on the same ceils 
(Leukemia 2000; 16:1413). Large numbers of cells are automati- 
cally scanned and their coordinates aved. MGG staining is 
removed and FISH is applied to the same slide. Small recipient- 
derived populations are targeted and their images relocated to 
identify their morphology. Patients (pts) are informative for Duet 
analysis if they have cytogenetic abnormalities or sex-mismatched 
donors. Thirty-five serial tests were performed in 31 leukemia pts. 
Results were retrospectively correlated with outcome. Four pts 
were counted twice due to different results at different ime- 
points. Duet detected minute recipient type populations (<5%) in 
28 tests. In ten tests recipient ceils were mostly blasts and in 18 
they were mature hematopoietie c lls (MHC). Seven of the ten pts 
with blasts relapsed, 3 had TRM before clinical relapse could be 
documented. Among the 18 pts with MHC morphology, one had 
early TRM and none of the others relapsed (P=0.002). Duet had 
increased sensitivity in detection of host population when com- 
pared with standard FISH. Duet specificity in predicting relapse 
was also superior to FISH. Seventy percent of those with recipient 
type blasts relapsed compared to 25% of those with any recipient 
population as detected by FISH with no specified morphology 
(p=0.05). We started applying this system prospectively for clinical 
decision-making. In two pts minute recipient blast-population 
(<1%) was detected 1-3 months post-transplant, hmnune-suppres- 
sion was rapidly tapered off. One pt developed GVHD 2-weeks 
later, when she had I5% blasts, and spontaneously re-entered sus- 
tained remission. The other pt progressed espite further inter- 
ventions. Identification of residual recipient-type cells as blasts 
predicts imminent relapse and these patients need additional ther- 
apy. YVhen residual recipient cells are MHC, pts can be followed 
with serial testing and need not be subjected to the hazards of 
additional therapy. 
HISTOCO M PATIBILITY/ALTERNATIVE STEM 
CELL SOURCES 
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INTERLEUKIN-IO AND TUMOUR NECROSIS FACTOR ALPHA HAPLO- 
TYPES PREDICT TRANSPLANT RELATED MORTALITY AFTER UNRE- 
LATED DONOR STEM CELL TRANSPLANTS 
L Hows, J.3/I.1; Keem .J.-; Defor, T.S; Bidwell, J.L.2; Davies, S.M.S; 
Bradley, B.Ad I. Divisiol~ of 7;nmz~'pla~ztatio~l ScieTwes, Depavtmellt of 
Cl&icfll Medici~e, Utzivevsity of Bristol, Bristol, Ulzited Kilzgdom; 
2. 3/Ioleczdar btl, munogelzetics, DepavtmeTzt of Pathology aJzd Microbiol- 
ogy, UMversity of Bristol, Bristol, Ulzited KiTzgdom; 3. DepalwzleJzt of 
Boise Marrow Tra~spla77tatioJz aJtd Clhdcal Resea'rch, U1ffvevsity of 
Mi~zlzesota, Mimzeapolis, 3 I~  
]'here is evidence that serum levels of tumour necrosis factor- 
alpha (TNF-a) and IL-10 influence the probability of transplant 
related mortality (TRM) and acute graft versus host disease after 
HLA identical sibling stem cell transplantation (SCT). Certain 
genetic polymorphisms of these cytokines may also correlate with 
outconae of HLA matched unrelated onor SCT. We have stud- 
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